Q2 EPS Estimate for CytomX Therapeutics Lowered by Analyst

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Equities research analysts at Wedbush reduced their Q2 2025 earnings per share estimates for CytomX Therapeutics in a report issued on Monday, May 12th. Wedbush analyst R. Driscoll now expects that the biotechnology company will post earnings per share of ($0.14) for the quarter, down from their previous estimate of $0.13. Wedbush currently has a "Outperform" rating and a $6.00 target price on the stock. The consensus estimate for CytomX Therapeutics' current full-year earnings is ($0.05) per share. Wedbush also issued estimates for CytomX Therapeutics' Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.70) EPS, FY2027 earnings at ($0.66) EPS, FY2028 earnings at ($0.67) EPS and FY2029 earnings at $0.02 EPS.

Several other analysts also recently weighed in on the company. StockNews.com upgraded CytomX Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday, May 13th. HC Wainwright upgraded CytomX Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 price objective for the company in a report on Thursday. Finally, Piper Sandler lifted their price objective on CytomX Therapeutics from $2.50 to $5.00 and gave the company an "overweight" rating in a report on Thursday.

CytomX Therapeutics Stock Up 7.6%

Shares of CTMX stock traded up $0.16 on Wednesday, hitting $2.19. The stock had a trading volume of 2,807,476 shares, compared to its average volume of 2,064,686. The business has a 50 day moving average price of $0.82 and a 200 day moving average price of $0.89. The company has a market cap of $176.16 million, a PE ratio of 12.85 and a beta of 1.11. CytomX Therapeutics has a one year low of $0.40 and a one year high of $2.55.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $50.92 million during the quarter, compared to the consensus estimate of $35.42 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the previous year, the company posted $0.17 earnings per share.

Hedge Funds Weigh In On CytomX Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. purchased a new stake in shares of CytomX Therapeutics during the fourth quarter worth about $2,730,000. Woodline Partners LP purchased a new stake in shares of CytomX Therapeutics during the first quarter worth about $1,054,000. RA Capital Management L.P. purchased a new stake in CytomX Therapeutics in the first quarter valued at approximately $636,000. Prosight Management LP boosted its position in CytomX Therapeutics by 29.2% in the fourth quarter. Prosight Management LP now owns 3,905,000 shares of the biotechnology company's stock valued at $4,022,000 after buying an additional 882,891 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in CytomX Therapeutics by 288,736.3% in the fourth quarter. JPMorgan Chase & Co. now owns 811,630 shares of the biotechnology company's stock valued at $836,000 after buying an additional 811,349 shares during the last quarter. Hedge funds and other institutional investors own 67.77% of the company's stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.